Notice ID: 71a3f8080ed242c9999bffc0ee128569Award NoticeAwarded
Pre-Clinical Models of Infectious Diseases
Awarded on July 15, 2024. Full description on SAM.gov.
Awarded tounder 75N93024D00034 (source: SAM.gov award notice)• $146.3M
Description
Pre-Clinical Models of Infectious Diseases IDIQ Contracts IDIQ Guaranteed Minimum $2,500 Maximum Ordering Limit $146,300,000 Base Contract Number - 75N93024D00034 University of Florida UEI Number: NNFQH1JAPEP3 Awarded Task Area -C
Overview
Agency:
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Office:NATIONAL INSTITUTES OF HEALTH NIAID
Posted:July 25, 2024
NAICS:541714: Research and Development in Biotechnology (except Nanobiotechnology)
Last Updated:Dec 4, 2025
PSC:AN11: HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Set-Aside:Not specified
Type:Award Notice
Place of Performance:Columbus
Award Date:Jul 15, 2024
Award Amount (SAM.gov award notice):$146.3M
Award Overview
Award Number
75N93024D00034
Award Amount (SAM.gov award notice)
$146.3M
Award Date
Jul 15, 2024
Awardee
Awardee UEI
NNFQH1JAPEP3
Original Solicitation
Notice ID: 71a3f8080ed242c9999bffc0ee128569
Posted Date: Jul 25, 2024
Original Response Deadline: Not specified
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
NIHAI75N93023R00003- Market Research
- Pre-Solicitation
- Solicitation
- Awarded
This opportunity has been awarded.
- Market ResearchOct 21, 2022
Pre-Clinical Models of Infectious Diseases
- 2×Pre-SolicitationNov 30, 2022
Pre-Clinical Models of Infectious Diseases
- 5×SolicitationFeb 15, 2023
Pre-Clinical Models of Infectious Diseases
- 40×AwardedCurrentJul 25, 2024
Pre-Clinical Models of Infectious Diseases
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
See attached Sources Sought Notice and attached Draft Statement of Work. SOURCES SOUGHT NOTICE Solicitation Number: 75N98027R00005 Title: Quantitative Analysis of Longitudinal MR Images Classification Code/Title: AN11 - Health R&D Services; Health Care Services; Basic Research NAICS Code/Title: 541714 Research and Development in Biotechnology (except Nanobiotechnology) Size Standard: 1,000 employees Description: This is a Research and Development (R & D) Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential R & D requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Small businesses are encouraged to respond. Background: Since 1958, the Baltimore Longitudinal Study of Aging (BLSA) has been a major research program conducted by the National Institute on Aging (NIA). The BLSA is a multi-disciplinary study of physiologic and psychological aspects of normal aging in community-dwelling men and women. Active BLSA participants are volunteers who visit the Clinical Unit of the NIA-Intramural Research Program (IRP) in Baltimore, MD for testing every 1 to 4 years. Since 1994, the NIA has been conducting a longitudinal brain imaging study of older adults in the BLSA to characterize individual differences in longitudinal brain changes, to investigate the extent to which these brain changes underlie individual differences in cognitive aging, to identify brain changes that may be predictors of cognitive decline and Alzheimer’s disease, and to assess the impact of potential modulators of brain and cognitive aging. As of October, 2024, more than 4000 neuroimaging evaluations have been performed for BLSA participants. As part of this research program, it has also been necessary to develop and validate sophisticated tools for analysis of longitudinal neuroimaging data that can be applied in large-scale studies. Thus, this project has involved the development, validation, and refinement of novel image analysis tools and the application of these tools to longitudinal Magnetic Resonance (MR) imaging scans and Positron Emission Tomography (PET) measures of regional cerebral blood flow, amyloid and tau deposition in brain. More recently, these tools include advanced machine learning approaches using pattern analysis to classify clinical status and aging trajectories of individuals based on structural and functional brain images. The work of this requirement will continue to focus on the application of sophisticated tools and quantitative analysis of longitudinal MRI data acquired from BLSA participants. Thus, the proposed contract will apply methods developed in prior acquisitions, that allow continuity of research and provide longitudinal consistency of measures of global and regional brain volumes and ischemic lesion volumes, as well as functional MR data, including consistency with MR data acquired during earlier phases of this project (since 1994). This Contract will also require the application of sophisticated analytic approaches, including previously developed machine learning and pattern analysis methods, to allow classification of risk for cognitive impairment and likelihood of maintenance of cognitive resiience on an individual subject basis. Purpose and Objectives: The principal goal of this procurement is to provide quantification of MR imaging scans to provide measures of brain structure and function in BLSA participants, including heterogenous brain aging trajectories. Specifically, these data will allow NIA investigators to continue to address the following questions: What are the rates and regional distribution of changes in brain anatomy in non-demented men and women throughout adulthood? What is the frequency and progression of brain abnormalities in older adults and what is the clinical significance of these findings for cognitive aging? Against a background of age-related changes in brain structure, which changes predict cognitive impairment and Alzheimer’s disease, and conversely, what are the predictors of the maintenance of cognitive health or cognitive resilience? What factors modulate cognitive and brain aging and how do they impact brain-behavior associations? Project Requirements: See attached Draft Statement of Work. Anticipated Period of Performance: The anticipated period of performance is one year from date of award. Capability Statement/Information Sought: Companies that believe they possess the capabilities to provide the required products should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately. Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts and/or other government-wide acquisition contracts (GWACs) by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Capability statements must also include the Company Name, Unique Entity ID from SAM.gov, Physical Address, and Point of Contact Information. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. Interested companies are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Sneha Singh, Contract Specialist at e-mail address sneha.singh@nih.gov. The response must be received on or before Monday, November 9, 2026, 9:00 AM, Eastern Time. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in betaSAM. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). | Market Research | 541714 | No Set-Aside | 10/23/2026 | 11/09/2026 | Bethesda, MD | |
Pre-solicitation Notice Information Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases has a requirement to provide and develop animal models in order to advance our understanding of infectious diseases as well as advance the development of therapeutics and vaccines for infectious diseases. Description The National Institute of Allergy and Infectious Diseases (NIAID) supports and facilitates research that focuses on understanding, treating and, ultimately, preventing infectious, immunologic, and allergenic diseases. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports and facilitates research to understand, control and prevent human disease caused by infectious agents. Basic, applied and translational research to develop and assess therapeutics, vaccines, and diagnostics is supported through research grants, cooperative agreements, and contracts. In turn, DMID further supports and facilitates research ongoing under these funding mechanisms and through other programs via an array of preclinical and clinical resources and services to support multiples stages of the product development pipeline. These resources and services include genomic and gene sequencing services, provision of high quality biological materials, biocontainment facilities, and pre-clinical and clinical translational research resources (https://www.niaid.nih.gov/research/resources). The current NIAID Preclinical Models of Infectious Diseases IDIQ contract program is one of DMID’s preclinical services resources and supports the development and refinement of animal models and animal replacement models of infectious diseases, models that subsequently are used to evaluate candidate medical countermeasures against these diseases. In addition, these contracts facilitate regulatory submissions, patents, and other intellectual property applications by extramural investigators who request evaluation of their products. This program serves the DMID mission of supporting investigator-initiated research by providing critical data needed to apply for grant or other funding. Finally, these contracts enable product developers and sponsors to make key go/no-go decisions for candidate therapeutics, vaccines, and diagnostics. In addition to meeting the needs of extramural researchers, this program provides crucial data to our DHHS agency partners. These data will facilitate the advancement of promising candidate medical countermeasures against priority biodefense and emerging infectious agents to approval or licensure, and, in some cases, eventual deposit in the Strategic National Stockpile. As background, in 2024, 40 institutions were awarded base contracts under the Preclinical Models of Infectious Diseases IDIQ contract program. This program was a re-competition of her Animal Models of Infectious Diseases IDIQ contract program, and its overarching goal was to provide capability in a broad range of animal and animal replacement models for use in evaluating promising candidate countermeasures (vaccines, therapeutics, diagnostics) against the broad range of infectious agents that are in the purview of DMID. The breadth of the existing contractor pool has enabled a rapid and effective response to emerging infectious diseases, such as COVID-19, and emergency preparedness priorities. Awarded contracts were divided into 4 model-specific pools: Task Area A – Small Animal Models of Infectious Diseases Task Area B – Non-Human Primate Models of Infectious Diseases Task Area C – Animal Replacement and Non-traditional Animal Models of Infectious Diseases Task Area D – Generation and Distribution of Specialized Reagents The Preclinical Models of Infectious Diseases program will continue to provide the capability and capacity to develop and employ animal and animal replacement models (e.g., organ-on-a-chip technology) of infectious diseases for screening and product evaluation and addresses a critical stage in this pipeline by bridging in vitro testing and eventual clinical evaluation, including as needed, studies conducted under the guidance of 21 CFR 58, “Good Laboratory Practices”. In addition, for candidate products that are unable to be assessed for clinical efficacy in phase II or III trials for ethical or practical reasons, contracts awarded under this solicitation will enable regulatory approval or licensure via the guidance of the FDA’s Animal Efficacy Rule (21 CFR 314.610 and 601.91). This anticipated “ramp-on” solicitation will award multiple IDIQ base contracts to successful offerors that propose a general approach to the requirements, allowing them to join the existing contractor pools. Successful offerors will qualify for the pool and be eligible to compete for future task order awards in the existing model-specific Task Areas: Task Area A – Small Animal Models of Infectious Diseases Task Area B – Non-Human Primate Models of Infectious Diseases Task Area C – Animal Replacement and Non-traditional Animal Models of Infectious Diseases Task Area D – Generation and Distribution of Specialized Reagents Offerors are encouraged to consider submission of proposals to one or more of the above Task Areas (depending upon capabilities). Contract awards are anticipated to the organizations whose proposals offer the best value to the Government. For the purposes of this solicitation, the following definitions apply: Animal replacement tissue technologies derived from human or animal tissue (in particular lung, liver, immune system, brain, skin/soft tissue or gastrointestinal tissues): Organoids Organs on chips Artificial complex cell systems Microphysiological systems Tissue technologies derived from animals, in particular, non-human primates (for the purposes of bridging data from in vivo models with clinical data) Evaluation: encompasses advanced testing after a product has been screened and demonstrated as efficacious in the same or lower animal models; activities include dose refinement, measurement of host response, pharmacokinetics (in infected animals), pharmacodynamics (in infected animals), and therapeutic efficacy or immune protection against challenge. Model development: a novel systematic effort to reproduce a clinical syndrome caused by an infectious agent in an animal species following challenge with the agent and includes median lethal and/or infectious dose determination, natural history of infection, and serial pathogenesis studies. Model refinement: a systematic effort to improve the performance of an existing animal model that reproduces a clinical syndrome caused by an infectious agent; to adapt an existing animal model that reproduces a clinical syndrome caused by one infectious agent to a different, but related, infectious agent; to adapt an existing animal model to optimize its ability to support product screening or evaluation following challenge with the infectious agent. Non-human primate models: new and old-world species, including but not limited to Macaca, spp. (cynomolgus, Rhesus, pig-tailed); Chlorocebus, spp. (African green monkeys, vervets); Aotus, spp.; Papio, spp.; Callithrix, spp. (marmosets) Non-traditional animal models including but not limited to: Domestic livestock: horses, cattle, goats, sheep, fowl Wildlife species: marmots, wild rodents, deer, bats Invertebrates: snails, parasitic nematodes, parasitic protozoa, insect vectors of human disease Aquatic: zebrafish HFIM Pathogens: infectious bacteria, viruses, parasites, fungi, toxins, and other agents such as prions that cause clinical syndromes in humans (surrogate human pathogen/animal combinations may be used for diseases where human pathogens cannot be studied in animal models) Products: agents for the prevention of infectious diseases such as vaccines or microbicides; therapeutics targeting the host or the pathogen, including conventional drugs, immunotherapeutics, and therapeutic vaccines; and diagnostics (Also referred to as candidate medical countermeasures or countermeasures.) Reagents: biochemical, genomic, molecular, cellular, and immunologic materials integral to research on pathogens, including the pathogenic agent or toxin itself requiring an in vivo model for production (e.g., hybridomas, monoclonal antibodies, otherwise unculturable organisms, live vectors) Screening: encompasses early-stage or first-in-animal testing for product effectiveness in animals; activities include rudimentary testing of product effectiveness after challenge, determination of maximum tolerated dose, and minimum effective dose. Small animal models: includes but is not limited to traditional laboratory rodent species (mice, rats, hamsters, gerbils (including jirds), guinea pigs), transgenic, humanized knock-out, and knock-in mouse strains, cotton rats, laboratory rabbit varieties, and laboratory ferrets The services encompass the following: Small animal models: development of new and refinement of existing models amenable for evaluating candidate countermeasures; evaluation of candidate countermeasures, including but not limited to, maximum tolerated dose, minimum effective dose, safety, efficacy, pharmacokinetics, pharmacodynamics Non-human primate models: development of new and refinement of existing models amenable for evaluating candidate countermeasures; evaluation of candidate countermeasures, including but not limited to, maximum tolerated dose, minimum effective dose, safety, efficacy, pharmacokinetics, pharmacodynamics Animal replacement models and non-traditional animal models: development of new and refinement of existing models amenable for evaluating candidate countermeasures; evaluation of candidate countermeasures, including but not limited to, maximum tolerated dose, minimum effective dose, safety, efficacy, pharmacokinetics, pharmacodynamics studies to bridge animal and animal replacement model Generation and Distribution of Specialized Reagents including but not limited to: Production of live life cycle stages for parasitic infections (e.g., eggs, pupae, larvae, adult stage parasites) Production of live vectors that support life cycle stages of parasitic infections (e.g., mosquitoes, ticks, fleas, black flies, sand flies, tsetse flies, reduviid bugs) Tissues required for isolation of otherwise unculturable infectious agents or toxins that can be distributed as reagents Production of monoclonal and polyclonal antibodies and hybridomas in mice Model species that are not listed with the individual Task Areas above, but are requested for development or demonstrated as necessary for testing medical countermeasures following award, will be taken under advisement by the Government, and task order requirements involving these model species may be developed on a case-by-case basis as long as they are determined to represent benefit to the Government. The services shall be directed at, but not be limited to, the following areas of emphasis: RNA viruses with the potential to cause pandemics from the following viral families: Bunyaviridae Coronaviridae Enteroviridae (in particular, EV-D68 and EV-71) Filoviridae Flaviviridae (in particular dengue and West Nile viruses) Paramyxoviridae (in particular Hendra and Nipah viruses) Togaviridae Antimicrobial resistant and multi-drug resistant infections, including Methicillin- Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Clostridium difficile Diseases caused by pathogens and toxins on the National Institute of Allergy and Infectious Diseases (NIAID) Emerging Infectious Diseases/Pathogens list: http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/pages/cata.aspx ; in particular, influenza, viral hemorrhagic fevers (including arthropod-borne viruses), arthropod-borne encephalitis viruses, rabies, and Mycobacterium tuberculosis (including MDR and XDR strains), Bordetella pertussis, Group A Streptococcus; Fungal diseases, including invasive aspergillosis, candidiasis, coccidioidomycosis, cryptococcosis, mucormycosis , pneumocystis pneumonia; Non-Biodefense Bacteria, including Chlamydophila pneumonia, Haemophilus, spp., Legionella, spp, non-tuberculous Mycobacterial spp., Streptococcus pneumoniae, Non-Biodefense Viruses, including: adenoviruses Hepatitis B and C viruses, Herpesviruses (HSV 1 and 2, CMV, VZV, HHV-6/7), human metapneumovirus, respiratory syncytial virus, papillomaviruses, parainfluenza virus; Neglected tropical diseases, including: filariasis, leprosy, schistosomiasis, trachoma, trichomoniasis; and Sexually transmitted infections, including bacterial vaginosis, chlamydia, and gonorrhea The NIAID recognizes that a single organization or institution may not have the full spectrum of expertise or facilities required to perform all activities set forth in the Statement of Work. Contractors shall perform the work described in one or more Task Areas. Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through consortia agreements, partnerships, subcontracts, and/or consultants. However, contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management, and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order. Any responsible Offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about December 2026 and may be accessed through sam.gov. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. The content of the disc and online proposals must be identical. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.niaid.nih.gov and then click on "How to Submit." To submit online using eCPS, offerors must have a valid NIH electronic Research Administration (eRA) Commons account, which provides authentication and serves as a vehicle for secure transmission of documents and communication with the NIAID. The eRA Commons registration process may take up to 4 weeks. For more information, please see https://www.era.nih.gov/register-accounts/register-in-era-commons.htm.” | Pre-Solicitation | 541714 | No Set-Aside | 10/19/2026 | 12/07/2026 | - | |
SOURCES SOUGHT NOTICE – No. 75N98026R00175 Title: Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories Agency: National Institutes of Health (NIH) Description This is a SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources and (2) whether commercial sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. Purpose NIH is seeking information from qualified R&D firms, small businesses, and subcontractors regarding their capabilities to support the operation, consolidation, and/or recompete of one or more NIH-funded biorepositories for FY 2028, including at a minimum the NIDA Center for Genetic Studies (NCGS) and the NIH Brain Development Cohorts (NBDC) Biobank, which supports the Adolescent Brain Cognitive Development (ABCD) Study, and HEALthy Brain and Child Development (HBCD) Study. Background NIH currently supports over 20 biorepositories across 10+ Institutes and Centers, with each individual biorepository storing several thousands to over 3.5 million samples. NIH biorepositories have stored, analyzed, and distributed millions of samples of biomaterials to enable broad investigations into the myriad of biological and environmental factors that affect health, development, and disease. These repositories typically: Receive, process, store, and biosamples from a wide range of biospecimen types (e.g. blood/derivatives, fluids, DNA/RNA, hair, cell lines, iPSCs, teeth, fecal matter, birth specimens and other tissues such as brain and other organs) at various temperature and storage conditions (e.g. -80C, liquid nitrogen; fresh, frozen, paraffin-embedded, formalin-fixed) at scales ranging from tens of thousands to several million specimens. Serve dozens to hundreds of research studies across the United States and abroad. Enable broad, controlled-access biomaterial sharing to meet specific research objectives that further our knowledge of health Anticipate continued growth in biospecimen and data volume over the life of the award. Scope of Work & Required Capabilities Capable vendors should provide examples from current or previous projects when responding to capabilities. A. Sample Management and Storage Maintain secure, humidity- and temperature-controlled storage and tracking for at least 3,500,000 biospecimens in accordance with Best Practices, Clinical and Laboratory Standards, and Good Laboratory Practice (GLP; 21 CFR 58) with expert quality control and assurance procedures. Document the maximum capacity that could be achieved to expand storage beyond the minimum requested. Destroy samples per regulatory and consent requirements when no longer needed. College of American Pathologists (CAP) Biorepository Accreditation preferred. Maintain positive chain of custody and resolve data/sample discrepancies (missing data, incorrect information, misdirected samples) through issue tracking and resolution, coordinating with relevant receiving/data management teams (e.g. sites, site monitors, study staff). Receive de-identified clinical, diagnostic, environmental, and phenotypic data alongside biospecimens from funded grants/contracts. Centrally manage and cost-effectively distribute biosamples to qualified investigators approved through established access programs. Provide studies with collection kits and supplies, including barcoded tubes with human-readable labels. Provide research staff training for ordering supplies and collecting samples. B. Data Curation and Management Develop and maintain SOPs for sample receipt, storage, processing, QC, and distribution. Receive de-identified clinical, diagnostic, environmental, and phenotypic data associated with biospecimens from funded grants/contracts. Maintain an internal relational database (e.g., using persistent identifiers such as RRIDs) linked to associated data and participant and sample identifiers, with computerized inventory management and accurate tracking of sample and data location. Register and track biospecimens via an internal relational database with sample IDs (RRID) linked to participant IDs and associated data in the Contractor's auditable LIMS, with computerized inventory management and accurate tracking of sample/data location. Clean, standardize, and harmonize clinical data with cross-disorder phenotypic knowledge (e.g. different diagnostic systems or criteria, such as RDOC, DSM, ICD), incorporating data from electronic health records when applicable. Transfer data and sample IDs to controlled-access repositories or Data Centers (e.g., dbGAP, NBDC Data Hub or program specific data repositories). C. Laboratory and Analytic Capabilities Demonstrate laboratory expertise appropriate to the repository's sample types, which may include molecular biology techniques (e.g., DNA/RNA extraction, cell line transformation/immortalization), rigorous quality control, and tissue/cell culture (isolation, scale-up, and banking of primary cells). Provide CLIA-certification status. Provide laboratory capabilities for, but not limited to: metabolic, hematologic, and/or clinical assays high-throughput genotyping, sequencing, and gene-expression analysis Mass spectrometry for proteomics and metabolomics Advanced genomic and cellular techniques such as short- and long-range sequencing, chromatin capture, ChIP-seq, Cut-and-Tag, HiC generation of iPSC/neural stem cell lines CRISPR/Cas9 gene editing Analysis of RNA and DNA from Formalin-Fixed Parafin-Embedded tissue Provide scientific and technical expertise to evaluate and respond to researcher-submitted requests for biospecimen availability. Demonstrate that lead investigators and support staff have relevant experience in biobanking, LIMS, and database management Store and/or process histopathological tissue samples. Isolate, scale up, and bank primary cells from diverse tissue samples. D. Informatics Requirements and Cyberinfrastructure Develop, or manage and enhance (if already existing), a biorepository web portal (front-end and back-end), supporting existing features and providing updates/improvements as requested, potentially including: Synchronizing sample availability data with a public- or investigator-facing sample explorer tool to streamline discovery of related data and biospecimens across repositories Showcase published research and provide lay summaries Advertise repository resources For existing resources, support all currently available features, with updates and improvements as requested Where in scope, develop outreach tools (e.g., an integrated chatbot or public-facing portal) to help users locate biomaterials/data and discover related resources across repositories Develop or maintain backend infrastructure (e.g., server maintenance, microservices, relational databases such as PostgreSQL) and front-end website design/UI-UX. Maintain Authority to Operate (ATO) and require security documentation to keep systems compliant with applicable FISMA-level and other NIH requirements. Maintain, update, and develop Application Programming Interfaces (APIs) and cyberinfrastructure for secure, interoperable data exchange. Capabilities for homomorphic encryption and distributed learning. Demonstrate experience and technical expertise to address all aspects of informatics requirements listed above. K. Collaboration & Governance Establish a strong collaborative relationship with the NIH Data Centers, study teams, and Institutes/Centers to enable modifications as the studies evolve. Serve as a co-signatory of the Specimen/Material Transfer Agreements developed by the funding Institute/Center. Be eligible to receive a Certificate of Confidentiality, adhering to requirements for protecting sensitive participant information as set forth in 45 CFR Part 75.303(a), NIHGPS Chapter 8.3 and 15.2.1, and subsection 301(d) of the Public Health Service Act (see: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html). Comply with all applicable human subjects protection, ethical, privacy, and data security regulations. Submission Requirements Interested organizations must demonstrate and document in a submitted capability statement extensive experience across the technical areas above, and include specific information on: Experience — An outline of previous similar projects, specifically the techniques employed in the areas described above. Personnel — Name and professional qualifications of personnel with specific experience in the work requested and knowledge of/experience in biomedical research. Facilities — Availability and description of facilities and equipment required to conduct this type of work. The Government will assess the appropriateness of professional and technical personnel classifications and consider any other specific and relevant information that would improve evaluation of respondents. Organizations should demonstrate capability to administer and coordinate interrelated tasks effectively and in a timely manner. Supporting documentation may include contracts in which the organization performed equivalent tasks (Government and commercial), references (names, titles, phone numbers, and other identifying information), and awards or commendations. An organization that does not have all the listed expertise, may respond by listing organizations with which they intend to collaborate or have as subcontractors to fulfill the requirements. Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than October 20, 2026 at 1:00 PM EST. All capability statements should include: Company name and address Point of contact SAM.gov Unique Entity Identifier (UEI) Phone/fax/email NAICS Code(s) Business size and status Capability information responsive to the requirements and qualifications identified in this notice Type(s) of business, if any (e.g., small, Veteran-owned, service-disabled Veteran-owned, women-owned, 8(a), Small Disadvantaged Business (SDB), Historically Underutilized Business Zone (HUBZone)) NAICS Code: 541714 — Research and Development in Biotechnology (except Nanobiotechnology). SBA size standard: 1,000 employees or fewer. Submission Instructions Capability statements must be submitted electronically to: Shaun Rostad, Contract Specialist Email: shaun.rostad@nih.gov Secondary Point of Contact: Joshua T. Lazarus, Contract Specialist Email: josh.lazarus@nih.gov Submissions are due NO LATER THAN 1:00 p.m. EST on October 20, 2026. The subject line must include the Sources Sought Number. NIDA will not accept paper or faxed capability statements. Disclaimer THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement, nor does it constitute a solicitation or commitment by NIDA. The Government does not intend to award a contract based on responses under this announcement, nor otherwise pay for the preparation of any information submitted. Any proprietary information should be so marked. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Respondents should ensure their response is complete and sufficiently detailed to allow the Government to determine qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of information or provide feedback with respect to any information submitted. Based on the Government’s market research, it is the agency’s assessment that the services described herein do not appear to constitute commercial services as defined under RFO Subpart 2.1, and therefore, the agency does not currently intend to utilize RFO Part 12 Acquisition Procedures. However, if an interested party asserts that these services are in fact commercial in nature, it should respond to this requirement and provide supporting evidence demonstrating that the services meet the definition of commercial services as prescribed by the applicable regulations. | Market Research | 541714 | No Set-Aside | 10/01/2026 | 10/20/2026 | - | |
SOURCES SOUGHT NOTICE Title: Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories Agency: National Institutes of Health (NIH) Description This is a SMALL BUSINESS SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code 541714 should not submit a response to this notice. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. Purpose NIH is seeking information from qualified R&D firms, small businesses, and subcontractors regarding their capabilities to support the operation, consolidation, and/or recompete of one or more NIH-funded biorepositories for FY 2028, including at a minimum the NIDA Center for Genetic Studies (NCGS) and the NIH Brain Development Cohorts (NBDC) Biobank, which supports the Adolescent Brain Cognitive Development (ABCD) Study, and HEALthy Brain and Child Development (HBCD) Study. This notice also serves to determine the availability of all small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses) with the capability to perform this work. Background NIH currently supports over 20 biorepositories across 10+ Institutes and Centers, with each individual biorepository storing several thousands to over 3.5 million samples. NIH biorepositories have stored, analyzed, and distributed millions of samples of biomaterials to enable broad investigations into the myriad of biological and environmental factors that affect health, development, and disease. These repositories typically: Receive, process, store, and biosamples from a wide range of biospecimen types (e.g. blood/derivatives, fluids, DNA/RNA, hair, cell lines, iPSCs, teeth, fecal matter, birth specimens and other tissues such as brain and other organs) at various temperature and storage conditions (e.g. -80C, liquid nitrogen; fresh, frozen, paraffin-embedded, formalin-fixed) at scales ranging from tens of thousands to several million specimens. Serve dozens to hundreds of research studies across the United States and abroad. Enable broad, controlled-access biomaterial sharing to meet specific research objectives that further our knowledge of health Anticipate continued growth in biospecimen and data volume over the life of the award. Scope of Work & Required Capabilities Capable vendors should provide examples from current or previous projects when responding to capabilities. A. Sample Management and Storage Maintain secure, humidity- and temperature-controlled storage and tracking for at least 3,500,000 biospecimens in accordance with Best Practices, Clinical and Laboratory Standards, and Good Laboratory Practice (GLP; 21 CFR 58) with expert quality control and assurance procedures. Document the maximum capacity that could be achieved to expand storage beyond the minimum requested. Destroy samples per regulatory and consent requirements when no longer needed. College of American Pathologists (CAP) Biorepository Accreditation preferred. Maintain positive chain of custody and resolve data/sample discrepancies (missing data, incorrect information, misdirected samples) through issue tracking and resolution, coordinating with relevant receiving/data management teams (e.g. sites, site monitors, study staff). Receive de-identified clinical, diagnostic, environmental, and phenotypic data alongside biospecimens from funded grants/contracts. Centrally manage and cost-effectively distribute biosamples to qualified investigators approved through established access programs. Provide studies with collection kits and supplies, including barcoded tubes with human-readable labels. Provide research staff training for ordering supplies and collecting samples. B. Data Curation and Management Develop and maintain SOPs for sample receipt, storage, processing, QC, and distribution. Receive de-identified clinical, diagnostic, environmental, and phenotypic data associated with biospecimens from funded grants/contracts. Maintain an internal relational database (e.g., using persistent identifiers such as RRIDs) linked to associated data and participant and sample identifiers, with computerized inventory management and accurate tracking of sample and data location. Register and track biospecimens via an internal relational database with sample IDs (RRID) linked to participant IDs and associated data in the Contractor's auditable LIMS, with computerized inventory management and accurate tracking of sample/data location. Clean, standardize, and harmonize clinical data with cross-disorder phenotypic knowledge (e.g. different diagnostic systems or criteria, such as RDOC, DSM, ICD), incorporating data from electronic health records when applicable. Transfer data and sample IDs to controlled-access repositories or Data Centers (e.g., dbGAP, NBDC Data Hub or program specific data repositories). C. Laboratory and Analytic Capabilities Demonstrate laboratory expertise appropriate to the repository's sample types, which may include molecular biology techniques (e.g., DNA/RNA extraction, cell line transformation/immortalization), rigorous quality control, and tissue/cell culture (isolation, scale-up, and banking of primary cells). Provide CLIA-certification status. Provide laboratory capabilities for, but not limited to: metabolic, hematologic, and/or clinical assays high-throughput genotyping, sequencing, and gene-expression analysis Mass spectrometry for proteomics and metabolomics Advanced genomic and cellular techniques such as short- and long-range sequencing, chromatin capture, ChIP-seq, Cut-and-Tag, HiC generation of iPSC/neural stem cell lines CRISPR/Cas9 gene editing Analysis of RNA and DNA from Formalin-Fixed Parafin-Embedded tissue Provide scientific and technical expertise to evaluate and respond to researcher-submitted requests for biospecimen availability. Demonstrate that lead investigators and support staff have relevant experience in biobanking, LIMS, and database management Store and/or process histopathological tissue samples. Isolate, scale up, and bank primary cells from diverse tissue samples. D. Informatics Requirements and Cyberinfrastructure Develop, or manage and enhance (if already existing), a biorepository web portal (front-end and back-end), supporting existing features and providing updates/improvements as requested, potentially including: Synchronizing sample availability data with a public- or investigator-facing sample explorer tool to streamline discovery of related data and biospecimens across repositories Showcase published research and provide lay summaries Advertise repository resources For existing resources, support all currently available features, with updates and improvements as requested Where in scope, develop outreach tools (e.g., an integrated chatbot or public-facing portal) to help users locate biomaterials/data and discover related resources across repositories Develop or maintain backend infrastructure (e.g., server maintenance, microservices, relational databases such as PostgreSQL) and front-end website design/UI-UX. Maintain Authority to Operate (ATO) and require security documentation to keep systems compliant with applicable FISMA-level and other NIH requirements. Maintain, update, and develop Application Programming Interfaces (APIs) and cyberinfrastructure for secure, interoperable data exchange. Capabilities for homomorphic encryption and distributed learning. Demonstrate experience and technical expertise to address all aspects of informatics requirements listed above. K. Collaboration & Governance Establish a strong collaborative relationship with the NIH Data Centers, study teams, and Institutes/Centers to enable modifications as the studies evolve. Serve as a co-signatory of the Specimen/Material Transfer Agreements developed by the funding Institute/Center. Be eligible to receive a Certificate of Confidentiality, adhering to requirements for protecting sensitive participant information as set forth in 45 CFR Part 75.303(a), NIHGPS Chapter 8.3 and 15.2.1, and subsection 301(d) of the Public Health Service Act (see: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html). Comply with all applicable human subjects protection, ethical, privacy, and data security regulations. Submission Requirements Interested organizations must demonstrate and document in a submitted capability statement extensive experience across the technical areas above, and include specific information on: Experience — An outline of previous similar projects, specifically the techniques employed in the areas described above. Personnel — Name and professional qualifications of personnel with specific experience in the work requested and knowledge of/experience in biomedical research. Facilities — Availability and description of facilities and equipment required to conduct this type of work. The Government will assess the appropriateness of professional and technical personnel classifications and consider any other specific and relevant information that would improve evaluation of respondents. Organizations should demonstrate capability to administer and coordinate interrelated tasks effectively and in a timely manner. Supporting documentation may include contracts in which the organization performed equivalent tasks (Government and commercial), references (names, titles, phone numbers, and other identifying information), and awards or commendations. An organization that does not have all the listed expertise, may respond by listing organizations with which they intend to collaborate or have as subcontractors to fulfill the requirements. Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than October 20, 2026 at 1:00 PM EST. All capability statements should include: Company name and address Point of contact SAM.gov Unique Entity Identifier (UEI) Phone/fax/email NAICS Code(s) Business size and status Capability information responsive to the requirements and qualifications identified in this notice Type(s) of business, if any (e.g., small, Veteran-owned, service-disabled Veteran-owned, women-owned, 8(a), Small Disadvantaged Business (SDB), Historically Underutilized Business Zone (HUBZone)) NAICS Code: 541714 — Research and Development in Biotechnology (except Nanobiotechnology). SBA size standard: 1,000 employees or fewer. Submission Instructions Capability statements must be submitted electronically to: Shaun Rostad, Contract Specialist Email: shaun.rostad@nih.gov Secondary Point of Contact: Joshua T. Lazarus, Contract Specialist Email: josh.lazarus@nih.gov Submissions are due NO LATER THAN 1:00 p.m. EST on October 20, 2026. The subject line must include the Small Business Sources Sought Number. NIDA will not accept paper or faxed capability statements. Disclaimer THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement, nor does it constitute a solicitation or commitment by NIDA. The Government does not intend to award a contract based on responses under this announcement, nor otherwise pay for the preparation of any information submitted. Any proprietary information should be so marked. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Respondents should ensure their response is complete and sufficiently detailed to allow the Government to determine qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of information or provide feedback with respect to any information submitted. Based on the Government’s market research, it is the agency’s assessment that the services described herein do not appear to constitute commercial services as defined under RFO Subpart 2.1, and therefore, the agency does not currently intend to utilize RFO Part 12 Acquisition Procedures. However, if an interested party asserts that these services are in fact commercial in nature, it should respond to this requirement and provide supporting evidence demonstrating that the services meet the definition of commercial services as prescribed by the applicable regulations. | Market Research | 541714 | Total Small Business Set-Aside | 10/01/2026 | 10/20/2026 | - | |
SOURCES SOUGHT NOTICE Title: Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories Agency: National Institutes of Health (NIH) Description This is a SMALL BUSINESS SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code 541714 should not submit a response to this notice. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. Purpose NIH is seeking capability statements from small businesses, and subcontractors regarding their abilities to continue the work of the NIDA Center for Genetic Studies (NCGS) and the NIH Brain Development Cohorts (NBDC) Biobank, which supports the Adolescent Brain Cognitive Development (ABCD) Study, and HEALthy Brain and Child Development (HBCD) Study. This notice also serves to determine the availability of all small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses) with the capability to perform this work. Background NIH currently supports over 20 biorepositories across 10+ Institutes and Centers, with each individual biorepository storing several thousands to over 3.5 million samples. NIH biorepositories have stored, analyzed, and distributed millions of samples of biomaterials to enable broad investigations into the myriad of biological and environmental factors that affect health, development, and disease. These repositories typically: Receive, process, store, and biosamples from a wide range of biospecimen types (e.g. blood/derivatives, fluids, DNA/RNA, hair, cell lines, iPSCs, teeth, fecal matter, birth specimens and other tissues such as brain and other organs) at various temperature and storage conditions (e.g. -80C, liquid nitrogen; fresh, frozen, paraffin-embedded, formalin-fixed) at scales ranging from tens of thousands to several million specimens. Serve dozens to hundreds of research studies across the United States and abroad. Enable broad, controlled-access biomaterial sharing to meet specific research objectives that further our knowledge of health Anticipate continued growth in biospecimen and data volume over the life of the award. Scope of Work & Required Capabilities Capable vendors should provide examples from current or previous projects when responding to capabilities. A. Sample Management and Storage Maintain secure, humidity- and temperature-controlled storage and tracking for at least 3,500,000 biospecimens in accordance with Best Practices, Clinical and Laboratory Standards, and Good Laboratory Practice (GLP; 21 CFR 58) with expert quality control and assurance procedures. Document the maximum capacity that could be achieved to expand storage beyond the minimum requested. Destroy samples per regulatory and consent requirements when no longer needed. College of American Pathologists (CAP) Biorepository Accreditation preferred. Maintain positive chain of custody and resolve data/sample discrepancies (missing data, incorrect information, misdirected samples) through issue tracking and resolution, coordinating with relevant receiving/data management teams (e.g. sites, site monitors, study staff). Receive de-identified clinical, diagnostic, environmental, and phenotypic data alongside biospecimens from funded grants/contracts. Centrally manage and cost-effectively distribute biosamples to qualified investigators approved through established access programs. Provide studies with collection kits and supplies, including barcoded tubes with human-readable labels. Provide research staff training for ordering supplies and collecting samples. B. Data Curation and Management Develop and maintain SOPs for sample receipt, storage, processing, QC, and distribution. Receive de-identified clinical, diagnostic, environmental, and phenotypic data associated with biospecimens from funded grants/contracts. Maintain an internal relational database (e.g., using persistent identifiers such as RRIDs) linked to associated data and participant and sample identifiers, with computerized inventory management and accurate tracking of sample and data location. Register and track biospecimens via an internal relational database with sample IDs (RRID) linked to participant IDs and associated data in the Contractor's auditable LIMS, with computerized inventory management and accurate tracking of sample/data location. Clean, standardize, and harmonize clinical data with cross-disorder phenotypic knowledge (e.g. different diagnostic systems or criteria, such as RDOC, DSM, ICD), incorporating data from electronic health records when applicable. Transfer data and sample IDs to controlled-access repositories or Data Centers (e.g., dbGAP, NBDC Data Hub or program specific data repositories). C. Laboratory and Analytic Capabilities Demonstrate laboratory expertise appropriate to the repository's sample types, which may include molecular biology techniques (e.g., DNA/RNA extraction, cell line transformation/immortalization), rigorous quality control, and tissue/cell culture (isolation, scale-up, and banking of primary cells). Provide CLIA-certification status. Provide laboratory capabilities for, but not limited to: metabolic, hematologic, and/or clinical assays high-throughput genotyping, sequencing, and gene-expression analysis Mass spectrometry for proteomics and metabolomics Advanced genomic and cellular techniques such as short- and long-range sequencing, chromatin capture, ChIP-seq, Cut-and-Tag, HiC generation of iPSC/neural stem cell lines CRISPR/Cas9 gene editing Analysis of RNA and DNA from Formalin-Fixed Parafin-Embedded tissue Provide scientific and technical expertise to evaluate and respond to researcher-submitted requests for biospecimen availability. Demonstrate that lead investigators and support staff have relevant experience in biobanking, LIMS, and database management Store and/or process histopathological tissue samples. Isolate, scale up, and bank primary cells from diverse tissue samples. D. Informatics Requirements and Cyberinfrastructure Develop, or manage and enhance (if already existing), a biorepository web portal (front-end and back-end), supporting existing features and providing updates/improvements as requested, potentially including: Synchronizing sample availability data with a public- or investigator-facing sample explorer tool to streamline discovery of related data and biospecimens across repositories Showcase published research and provide lay summaries Advertise repository resources For existing resources, support all currently available features, with updates and improvements as requested Where in scope, develop outreach tools (e.g., an integrated chatbot or public-facing portal) to help users locate biomaterials/data and discover related resources across repositories Develop or maintain backend infrastructure (e.g., server maintenance, microservices, relational databases such as PostgreSQL) and front-end website design/UI-UX. Maintain Authority to Operate (ATO) and require security documentation to keep systems compliant with applicable FISMA-level and other NIH requirements. Maintain, update, and develop Application Programming Interfaces (APIs) and cyberinfrastructure for secure, interoperable data exchange. Capabilities for homomorphic encryption and distributed learning. Demonstrate experience and technical expertise to address all aspects of informatics requirements listed above. K. Collaboration & Governance Establish a strong collaborative relationship with the NIH Data Centers, study teams, and Institutes/Centers to enable modifications as the studies evolve. Serve as a co-signatory of the Specimen/Material Transfer Agreements developed by the funding Institute/Center. Be eligible to receive a Certificate of Confidentiality, adhering to requirements for protecting sensitive participant information as set forth in 45 CFR Part 75.303(a), NIHGPS Chapter 8.3 and 15.2.1, and subsection 301(d) of the Public Health Service Act (see: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html). Comply with all applicable human subjects protection, ethical, privacy, and data security regulations. Submission Requirements Interested organizations must demonstrate and document in a submitted capability statement extensive experience across the technical areas above, and include specific information on: Experience — An outline of previous similar projects, specifically the techniques employed in the areas described above. Personnel — Name and professional qualifications of personnel with specific experience in the work requested and knowledge of/experience in biomedical research. Facilities — Availability and description of facilities and equipment required to conduct this type of work. The Government will assess the appropriateness of professional and technical personnel classifications and consider any other specific and relevant information that would improve evaluation of respondents. Organizations should demonstrate capability to administer and coordinate interrelated tasks effectively and in a timely manner. Supporting documentation may include contracts in which the organization performed equivalent tasks (Government and commercial), references (names, titles, phone numbers, and other identifying information), and awards or commendations. An organization that does not have all the listed expertise, may respond by listing organizations with which they intend to collaborate or have as subcontractors to fulfill the requirements. Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than October 20, 2026 at 1:00 PM EST. All capability statements should include: Company name and address Point of contact SAM.gov Unique Entity Identifier (UEI) Phone/fax/email NAICS Code(s) Business size and status Capability information responsive to the requirements and qualifications identified in this notice Type(s) of business, if any (e.g., small, Veteran-owned, service-disabled Veteran-owned, women-owned, 8(a), Small Disadvantaged Business (SDB), Historically Underutilized Business Zone (HUBZone)) NAICS Code: 541714 — Research and Development in Biotechnology (except Nanobiotechnology). SBA size standard: 1,000 employees or fewer. Submission Instructions Capability statements must be submitted electronically to: Shaun Rostad, Contract Specialist Email: shaun.rostad@nih.gov Secondary Point of Contact: Joshua T. Lazarus, Contract Specialist Email: josh.lazarus@nih.gov Submissions are due NO LATER THAN 1:00 p.m. EST on October 20, 2026. The subject line must include the Small Business Sources Sought Number. NIDA will not accept paper or faxed capability statements. Disclaimer THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement, nor does it constitute a solicitation or commitment by NIDA. The Government does not intend to award a contract based on responses under this announcement, nor otherwise pay for the preparation of any information submitted. Any proprietary information should be so marked. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Respondents should ensure their response is complete and sufficiently detailed to allow the Government to determine qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of information or provide feedback with respect to any information submitted. Based on the Government’s market research, it is the agency’s assessment that the services described herein do not appear to constitute commercial services as defined under RFO Subpart 2.1, and therefore, the agency does not currently intend to utilize RFO Part 12 Acquisition Procedures. However, if an interested party asserts that these services are in fact commercial in nature, it should respond to this requirement and provide supporting evidence demonstrating that the services meet the definition of commercial services as prescribed by the applicable regulations. | Market Research | 541714 | Total Small Business Set-Aside | 09/28/2026 | 10/20/2026 | - |
Additional Details
Solicitation Number
NIHAI75N93023R00003
Archive Date
Jul 30, 2024
Office Address
BETHESDA, MD, 20892